UK Markets closed

Kintara Therapeutics, Inc. (KTRA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.5734-0.0566 (-8.98%)
At close: 04:00PM EST
0.5755 +0.00 (+0.37%)
After hours: 07:27PM EST

Kintara Therapeutics, Inc.

12707 High Bluff Drive
Suite 200
San Diego, CA 92130
United States
858 350 4364

Full-time employees4

Key executives

NameTitlePayExercisedYear born
Mr. Saiid Zarrabian B.Sc., MBAPres, CEO & Director822.5kN/A1953
Dr. Dennis M. BrownCo-Founder & Chief Scientific Officer200kN/A1950
Mr. Scott Praill B.Sc., C.P.A., CA, CPA, BScCFO & Sec.366kN/A1967
Mr. Jeffrey A. BachaFounderN/AN/A1968
Mr. Greg A. JohnsonActing Head of OperationsN/AN/AN/A
Mr. John LiatosSr. VP of Bus. Devel.N/AN/A1968
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California.

Corporate governance

Kintara Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.